Genmab A/S (NASDAQ:GMAB) Receives $49.50 Consensus Target Price from Brokerages

Shares of Genmab A/S (NASDAQ:GMAB) have been assigned a consensus rating of “Hold” from the twelve ratings firms that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $49.50.

A number of research analysts have issued reports on GMAB shares. Royal Bank of Canada upgraded shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Thursday, July 18th. Truist Financial raised their target price on shares of Genmab A/S from $50.00 to $53.00 and gave the company a “buy” rating in a report on Tuesday, June 4th. Finally, BTIG Research upped their price target on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday, June 27th.

Genmab A/S Trading Up 0.4 %

NASDAQ:GMAB opened at $28.48 on Tuesday. The stock has a 50 day simple moving average of $27.01 and a 200 day simple moving average of $28.35. Genmab A/S has a 1-year low of $24.53 and a 1-year high of $41.58. The stock has a market cap of $18.84 billion, a P/E ratio of 23.73, a PEG ratio of 1.01 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. Genmab A/S had a net margin of 30.74% and a return on equity of 18.90%. The company had revenue of $603.30 million during the quarter, compared to analysts’ expectations of $594.23 million. As a group, sell-side analysts forecast that Genmab A/S will post 1.13 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Capital International Investors increased its holdings in shares of Genmab A/S by 7.8% during the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after buying an additional 315,355 shares in the last quarter. Harding Loevner LP increased its holdings in Genmab A/S by 2.7% in the 4th quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock worth $97,569,000 after purchasing an additional 85,665 shares in the last quarter. First Trust Advisors LP raised its position in Genmab A/S by 16.0% in the fourth quarter. First Trust Advisors LP now owns 1,270,095 shares of the company’s stock valued at $40,440,000 after purchasing an additional 175,292 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Genmab A/S during the fourth quarter valued at about $5,912,000. Finally, PNC Financial Services Group Inc. boosted its stake in shares of Genmab A/S by 5.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 165,187 shares of the company’s stock valued at $5,260,000 after purchasing an additional 8,463 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.